AIM at Melanoma

Home
AIM at Melanoma

AIM at Melanoma Foundation is a non-profit organization committed to Information & Support
Both in the U.S.

AIM’s Mission
By directing and funding paradigm-shifting research initiatives; educating patients, healthcare professionals, and the public; and advocating for survivors and their families, AIM at Melanoma’s goal is to end this disease in our lifetime while improving the lives of those it affects. Founded in 2004, AIM at Melanoma is a global foundation dedicated to finding more effective treatment

s and, ultimately, the cure for melanoma. AIM at Melanoma is dedicated to:

Innovation in Melanoma Research
We believe that the cure for melanoma will be found more quickly by bringing together leading global researchers and funding their collaborative research. Our paradigm-shifting global research initiatives, including the International Melanoma Tissue Bank Consortium, are poised to reshape the future of melanoma. Legislation, Policy & Advocacy
We are the respected voice of melanoma across the nation. When drugs are approved, legislation is drafted, and research is assessed, AIM is at the table, speaking loudly and clearly on behalf of patients and their families. We are trusted advisors for government agencies, medical boards, and pharmaceutical companies on critical topics that affect melanoma patients. and on a global level we provide comprehensive, easy-to-access melanoma resources for patients and health care professionals. AIM’s patient, family, and caregiver support offerings—such as our Ask an Expert service, which allows patients to contact a melanoma physician assistant with their questions, and our Peer Connect program, which matches newly diagnosed patients with melanoma veterans—serve as models for other cancer foundations.

10/06/2026

Randomization is a process used in many clinical trials to assign participants to different treatment groups by chance, similar to flipping a coin or using a computer-generated system.

Randomization helps researchers compare treatments fairly and accurately. It reduces bias and helps ensure that differences in outcomes are more likely due to the treatment being studied rather than other factors.

In a randomized clinical trial, participants may receive:
• The current standard treatment
• A new treatment being studied
• Different treatment combinations or sequences

Randomization does not mean patients receive “no treatment.” In cancer clinical trials, patients typically receive at least the current standard of care, unless the study is specifically designed differently and clearly explained during informed consent.

Some trials are also “blinded,” meaning patients and/or researchers may not know which treatment group a participant is in until the study is completed.

Randomization is an important part of how researchers determine whether new melanoma treatments are safe, effective, and potentially better than existing approaches.

Understanding terms like randomization can help patients feel more informed when considering participation in a clinical trial.

Learn more about melanoma clinical trials and patient education resources at AIMatMelanoma.org

Address

Telephone

+18332363635

Website

http://www.AIMatMelanoma.org/

Alerts

Be the first to know and let us send you an email when AIM at Melanoma posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts